<?xml version="1.0" encoding="UTF-8"?>
<ref id="B54-vaccines-08-00043">
 <label>54.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cox</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Kwaks</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Brandenburg</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Koldijk</surname>
    <given-names>M.H.</given-names>
   </name>
   <name>
    <surname>Klaren</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Smal</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Korse</surname>
    <given-names>H.J.</given-names>
   </name>
   <name>
    <surname>Geelen</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Tettero</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Zuijdgeest</surname>
    <given-names>D.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>HA Antibody-Mediated FcgammaRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids</article-title>
  <source>Front. Immunol.</source>
  <year>2016</year>
  <volume>7</volume>
  <fpage>399</fpage>
  <pub-id pub-id-type="doi">10.3389/fimmu.2016.00399</pub-id>
  <pub-id pub-id-type="pmid">27746785</pub-id>
 </element-citation>
</ref>
